​

Korro Bio Stock (NASDAQ:KRRO)

ForecastRevenueOwnershipFinancialsChart
Korro Bio by TradingView

Previous Close

$39.58

52W Range

$10.29 - $76.79

50D Avg

$35.35

200D Avg

$23.66

Market Cap

$376.39M

Avg Vol (3M)

$226.90K

Beta

2.89

Div Yield

-

KRRO Company Profile

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

112

IPO Date

Oct 03, 2019

Website

KRRO Performance

KRRO Financial Summary

Dec 24Dec 23Dec 22
Revenue$2.27M--
Operating Income$-91.91M$-84.53M$-59.00M
Net Income$-83.58M$-81.17M$-58.03M
EBITDA$-91.91M$-80.90M$-56.49M
Basic EPS$-9.37$-53.09$-227.58
Diluted EPS$-9.37$-53.08$-227.42

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
MBXMBX Biosciences, Inc. Common Stock
AUTLAutolus Therapeutics plc
QSIQuantum-Si incorporated
ADCTADC Therapeutics S.A.
RAPTRAPT Therapeutics, Inc.
ENGNenGene Holdings Inc.
DBVTDBV Technologies S.A.
RCKTRocket Pharmaceuticals, Inc.
CLLSCellectis S.A.
AMRNAmarin Corporation plc